New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:09 EDTSLXPSalix risk/reward favorable ahead of trial, says Stifel
Stifel is comfortable owning Salix ahead of the expected release of TARGET-3 retreatment data for Xifaxan in diarrhea-related IBS in coming weeks. The firm thinks the stock could rise significantly if the data is positive, while a decline in shares on negative results would create a buying opportunity. The firm thinks there is a 65%-70% chance that the data will be positive, and it estimates that the stock could climb up to 20%-25% on positive data. It keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTSLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTSLXPSalix initiated with a Hold at Deutsche Bank
Subscribe for More Information
July 17, 2014
05:24 EDTSLXPSalix, Pharming Group announces FDA approval of Ruconest
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use